A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade. When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain. Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity. This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles. DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases. CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors. Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile. Bupropion has demonstrated efficacy comparable to that of other antidepressants. However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bupropion is a second-generation AD that acts as a selective inhibitor of catecholamines' (noradrenaline and dopamine) reuptake, devoid of any serotonergic; antihistamine; or anticholinergic properties (Stahl et al., 2004).”
From Is There a Potential of Misuse for Venlafaxine and Bupropion? (2018) · cites this paper as Stahl et al., 2004
In the citing paper
“Inhibition of catecholamine reuptake is one of bupropion’s mechanisms of action [215].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, Jr., Freemantle, N., Mason, J., Eccles, M., & Boynton, J. (1999) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 107
RetractedGoodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“cause depression and modulate responses to antidepressants.(14,16,19) Several observations support an “upstream””
BackgroundUntreated Depression and Hippocampal Volume Loss
Sheline, Y. I., Gado, M. H., & Kraemer, H. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1516 · Cited by 1,180 · cited 1×
“Antidepressants may thus play a neuroprotective role, a possibility supported by observations that hippocampal neurogenesis may be required for the behavior effects of antidepressants in mice(23) and that progressive loss of hippocampal volume occurs during chronically untreated depression in humans.(24,25)”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“For example, antidepressants differ by more than 1000fold in potency at inhibiting monoamine reuptake, yet their efficacies are comparable and seemingly unrelated to potency.(21) Third, although all antidepressants enhance monoaminergic neurotransmission, they do so via disparate mechanisms, consistent with the possib…”
Background(2000) · PubMed · Cited by 685
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citation
Research works printed but not linked: 25
- Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monograph. 1993;11(1):2–14. [PubMed] [Google Scholar]
- GlaxoSmithKline. data on file, Research Triangle Park, NC. 2002. [Google Scholar]
- Stahl SM. Essential Psychopharmacology. 2nd ed. New York, NY: Cambridge University Press. 2000 [Google Scholar]
- Remeron [package, insert]. West Orange, NJ: Organon. 2002. [Google Scholar]
- Serzone [package, insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2002. [Google Scholar]
- Holden C. ed. Random samples: don't go off the Prozac. Science. 2003 301:760–761. [Google Scholar]
- Szabó Z, Àrgyelán M, and Kanyó B. et al. The effect of bupropion on the activity of dopamine transporter in depression: preliminary results [abstract]. Eur Neuropsychopharmacol. 2003 13(suppl 4):S210. [Google Scholar]
- American Psychiatric Association. Major Depressive Disorder: A Patient and Family Guide, 2001. Available at: www.psych.org. Accessed June 7, 2001. [Google Scholar]
- Geddes JR, Freemantle N, and Mason J. et al. SSRIs versus other anti-depressants for depressive disorder. Cochrane Database Syst Rev 2000(2):CD001851. [DOI] [PubMed] [Google Scholar]
- Thase ME, Haight BR, and Richard NE. et al. Remission rates following therapy with bupropion or SSRIs. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion [poster]. Presented at the 146th annual meeting of the American Psychiatric Association. 22–27May1993 San Francisco, Calif. [Google Scholar]
- Yeghiya M, Danielyan A, and Khachatur G. et al. Augmentation of SSRIs with bupropion in treatment resistant depression in adolescents [abstract]. Presented at the 156th annual meeting of the American Psychiatric Association. 17–22May2003 San Francisco, Calif. [Google Scholar]
- DeBattista C, Solvason HB, and Fleming S. et al. A placebo-controlled, double-blind study of bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 154th annual meeting of the American Psychiatric Association. 5–10May2001 New Orleans, La. [DOI] [PubMed] [Google Scholar]
- Solvason HB, DeBattista C, and Kendrick E. et al. Bupropion SR in the treatment of SSRI-induced sexual dysfunction [poster]. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit Program (NCDEU). May 30–June 2, 2000 Boca Raton, Fla. [Google Scholar]
- Johnston JA, Schmidt G, and Ascher J. et al. Pharmacokinetic optimization of bupropion SR for smoking cessation. Drugs. 2002 62(suppl 2):11–24. [DOI] [PubMed] [Google Scholar]
- Hudziak JJ, Wilens TE, and Rosenthal NE. et al. The efficacy of extended-release bupropion in adult ADHD [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Rosenthal NE, Modell JG, and Harriett A. et al. Wellbutrin XL for the prevention of seasonal depressive episodes [poster]. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology. 7–11December2003 San Juan, Puerto Rico. [Google Scholar]
- Clayton AH, West SG. The effects of antidepressants on human sexuality. Primary Psychiatry. 2003;10:62–70. [Google Scholar]
- Westlund R, Haight BR, and Harriett A. et al. Effect on body weight of bupropion in patients with major depression [poster]. Presented at the 16th Annual US Psychiatric & Mental Health Congress. 6–9November2003 Orlando, Fla. [Google Scholar]
- Celexa [package, insert]. St Louis, Mo: Forest Laboratories. 2002. [Google Scholar]
- Prozac [package, insert]. Indianapolis, Ind: Eli Lilly and Company. 2002. [Google Scholar]
- Paxil [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
- Zoloft [package, insert]. New York, NY: Pfizer Inc. 2002. [Google Scholar]
- Effexor [package, insert]. Philadelphia, Pa: Wyeth. 2002. [Google Scholar]
- Wellbutrin [package, insert]. Research Triangle Park, NC: GlaxoSmithKline. 2002. [Google Scholar]
Cited by
Items 101–200 of 510
Billes, S. K., & Cowley, M. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301526 · Cited by 52
“Like many antidepressants and the only centrally acting, FDA-approved long-term obesity treatment, sibutramine (Meridias), BUP inhibits biogenic amine plasma membrane reuptake transporters (Ascher et al, 1995; Stahl et al, 2004; Kaplan, 2005).”
BackgroundNathoo, N., & Mackie, A. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.10.004 · Cited by 51
Clark, A., Tate, B., Urban, B., Schroeder, R., Gennuso, S. A., Ahmadzadeh, S., McGregor, D., Girma, B., Shekoohi, S., & Kaye, A. D. (2023) · Health Psychology Research · doi:10.52965/001c.81043 · Cited by 52
Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review
Saini, N., Singh, N., Kaur, N., Garg, S., Kaur, M., Kumar, A., Verma, M., Singh, K., & Sohal, H. S. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03203-5 · Cited by 51
“Bupropion 29 enhances the monoaminergic activity by delaying norepinephrine and dopamine concentration and duration in the synaptic cleft by reducing neuronal reuptake [113].”
Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1805435 · Cited by 46
“Whereas, bupropion is a moderately effective antidepressant when taken alone, thought to act by preventing dopamine and noradrenaline reuptake [228].”
BackgroundNoradrenaline is necessary for the hedonic properties of addictive drugs
Jasmin, L., Mena, N., & Tien, D. A. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.08.030 · Cited by 46
Relationship between anti-depressant use and lung cancer survival
Zingone, A., Brown, D., Bowman, E. D., Vidal, O. M., Sage, J., Neal, J., & Ryan, B. M. (2017) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2017.01.001 · Cited by 42
“NDRIs mainly function by inhibiting the reuptake of dopamine and norepinephrine.(22,23) Recent studies have provided mechanistic evidence for a link between these neurotransmitters and cancer.”
BackgroundAng, Y.-S., Kaiser, R., Deckersbach, T., Almeida, J., Phillips, M. L., Chase, H. W., Webb, C. A., Parsey, R., Fava, M., McGrath, P., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.04.009 · Cited by 43
Restless legs syndrome induced by citalopram: a psychiatric emergency?
Perroud, N. A., Lazignac, C., Baleydier, B., Cicotti, A., Maris, S., & Damsa, C. (2006) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2006.10.006 · Cited by 44
“Bupropion inhibits dopamine reuptake [9] and has shown to be effective in RLS [10] without dopamine-like side effects (levodopa), such as rebound and tolerance [1].”
BackgroundKline, R. L., Zhang, S., Farr, O. M., Hu, S., Záborszky, L., Samanez-Larkin, G. R., & Li, C. R. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00149 · Cited by 45
Zhou, Q., Li, X., Yang, D., Xiong, C., & Xiong, Z. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114431 · Cited by 47
A Systematic Review of Pharmacological Treatments for Internet Gaming Disorder
de Sá, R. R. C., Coelho, S. G., Parmar, P. K., Johnstone, S., Kim, H. S. A., & Tavares, H. (2023) · Psychiatry Investigation · doi:10.30773/pi.2022.0297 · Cited by 51
Raskin, S., & Durst, R. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.07.024 · Cited by 42
Simmler, L. D., Wandeler, R., & Liechti, M. E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-220 · Cited by 46
Novel Molecular Targets of Antidepressants
Jarończyk, M., & Walory, J. (2022) · Molecules · doi:10.3390/molecules27020533 · Cited by 48
Zaki, M. R., Varshosaz, J., & Fathi, M. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2014.12.031 · Cited by 40
No Evidence for a Major Role of Polymorphisms During Bupropion Treatment
Hu, J., Redden, D. T., Berrettini, W. H., Shields, P. G., Restine, S. L., Pinto, A., Lerman, C., & Allison, D. B. (2006) · Obesity · doi:10.1038/oby.2006.215 · Cited by 39
“Bupropion, an antidepressant medication with effects on dopamine reuptake (3), has proven efficacious for both smoking cessation (4) and weight loss (5).”
BackgroundCan MDMA Play a Role in the Treatment of Substance Abuse?
Jerome, L., Schuster, S., & Yazar-Klosinski, B. (2013) · Current Drug Abuse Reviews · doi:10.2174/18744737112059990005 · Cited by 37
Müller, F., Holze, F., Dolder, P., Ley, L., Vizeli, P., Soltermann, A., Liechti, M. E., & Borgwardt, S. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00906-2 · Cited by 38
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew, J., & Novick, A. M. (2021) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13283 · Cited by 46
Geracioti, T. D., Jefferson-Wilson, L., Strawn, J. R., Baker, D. G., Dashevsky, B. A., Horn, P. S., & Ekhator, N. N. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.023 · Cited by 44
Is There a Potential of Misuse for Venlafaxine and Bupropion?
Schifano, F., & Chiappini, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00239 · Cited by 38
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
Dean, Z., Horndasch, S., Giannopoulos, P., & McCabe, C. (2016) · Psychological Medicine · doi:10.1017/s003329171600088x · Cited by 40
“It has been suggested, however, that catecholamine antidepressants like bupropion (dopamine and noradrenaline reuptake inhibitor, DNRI) (Stahl et al. 2004; Dwoskin et al. 2006) might be more efficacious at improving reward-related deficits and apathy in depression and less likely to cause the negative sideeffects of s…”
BackgroundEffects of acute bupropion administration on locomotor activity in adolescent and adult mice
Redolat, R., Vidal, J., mez, M. C. G., & Carrasco, M. C. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200502000-00007 · Cited by 41
“It inhibits the reuptake of dopamine and norepinephrine (Stahl et al., 2004) and also acts as a noncompetitive antagonist of nicotinic acetylcholine receptors (Slemmer et al.”
BackgroundThe antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors
Pandhare, A., Pappu, A. S., Wilms, H., Blanton, M., & Jansen, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.021 · Cited by 39
Khan, S. R., Berendt, R. T., Ellison, C. D., Ciavarella, A. B., Asafu-Adjaye, E. B., Khan, M. A., & Faustino, P. J. (2016) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/bs.podrm.2015.12.001 · Cited by 39
Bupropion in the Depression-Related Sexual Dysfunction: A Systematic Review
Pereira, V., Arias-Carrion, O., Machado, S., Nardi, A., & Silva, A. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612112630 · Cited by 36
“Bupropion, which is a norepinephrine and dopamine reuptake inhibitor, does not have an effect on serotoninergic system but acts on dopamine and norepinephrine transporters, enhancing monoaminergic function, with the subsequent reuptake inhibition of these 2 neurotransmitters [10, 44].”
BackgroundCatecholaminergic based therapies for functional recovery after TBI
Osier, N. D., & Dixon, C. E. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.026 · Cited by 39
“…inflammation can be achieved by targeting DA pathways; for example, the selective norepinephrine and dopamine reuptake inhibitor buproprion (Stahl et al., 2004), which is used traditionally to treat depression, has also been found to have anti-inflammatory effects following brain injury…”
BackgroundSuryanto, M. E., Audira, G., Uapipatanakul, B., Hussain, A., Saputra, F., Siregar, P., Chen, K. H. ‐., & Hsiao, C. (2021) · Cells · doi:10.3390/cells10040738 · Cited by 37
“15 NDRI Inhibit reuptake of noradrenaline and dopamine [58] Bupropion (BUP) Seizures, nonepileptic myoclonus, and confusion [59]”
BackgroundNiosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling
Harini, K., Alomar, S. Y., Mohammed, V., Manoharadas, S., Thirumalai, A., Girigoswami, K., & Girigoswami, A. (2024) · Pharmaceuticals · doi:10.3390/ph17030366 · Cited by 40
“Although drugs that belong to the SSRI class are preferred as the first-line medication, bupropion is given as an adjuvant when patients fail to respond to SSRIs and is more effective than them [35].”
BackgroundHigh Prevalence of Psychotropics Overdose among Suicide Attempters in Korea
Kim, J., Kim, M., Kim, Y.-R., Choi, K. H., & Lee, K. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.3.302 · Cited by 37
The Clinical Manifestations of Polycystic Ovary Syndrome (PCOS) and The Treatment Options
Karkera, S., Agard, E., & Sankova, L. (2023) · European Journal of Biology and Medical Science Research · doi:10.37745/ejbmsr.2013/vol11n15791 · Cited by 52
Abri, S. A. A., Orengo, J. P., Hayashi, S., Thoren, K. L., Benowitz, N. L., & Olson, K. R. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.849349 · Cited by 35
The Role of Glutamate Underlying Treatment-resistant Depression
Kim, J., Kim, T.-E., Lee, S., & Koo, J. W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.22.1034 · Cited by 41
“ily more selective for dopamine transporters than for norepinephrine transporters [42].”
BackgroundMoll, J. L., & Brown, C. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02190.x · Cited by 36
Additional Evidence of the Abuse Potential of Bupropion
Reeves, R. R., & Ladner, M. E. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318295fe2f · Cited by 39
Substrate binding and inhibition mechanism of norepinephrine transporter
Ji, W., Miao, A., Liang, K., Liu, J., Qi, Y., Zhou, Y., Duan, X., Sun, J., Lai, L., & Wu, J.-X. (2024) · Nature · doi:10.1038/s41586-024-07810-5 · Cited by 34
“Bupropion exerts its therapeutical functions by inhibiting both NA and dopamine reuptake, with lower potency for NET 14,15 .”
The aqueous stability of bupropion
O’Byrne, P. M., Williams, R., Walsh, J. J., & Gilmer, J. F. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.04.024 · Cited by 33
Shalabi, A. R., Walther, D. M., Baumann, M. H., & Glennon, R. A. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00055 · Cited by 33
Zhou, M., Wang, Q., Zheng, C., Rush, A. J., Volkow, N. D., & Xu, R. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-01011-y · Cited by 33
Detecting Drug Promiscuity Using Gaussian Ensemble Screening
Pérez‐Nueno, V. I., Venkatraman, V., Mavridis, L., & Ritchie, D. W. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3000979 · Cited by 34
Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature
Kumar, S., Kodela, S., Detweiler, J. G., Kim, K. Y., & Detweiler, M. B. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.07.001 · Cited by 32
“contribute to its psychotropic effects [4–6].”
BackgroundInfluentialVarScan2 analysis of de novo variants in monozygotic twins discordant for schizophrenia
Reble, E., Castellani, C. A., Melka, M. G., O’Reilly, R., & Singh, S. M. (2017) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000162 · Cited by 31
“The therapeutic actions of bupropion, an antidepressant, are not well understood, but it is believed to block dopamine reuptake (Stahl et al., 2004).”
BackgroundWalsh, A. E. L., Huneke, N. T. M., Brown, R. E., Browning, M. D., Cowen, P. J., & Harmer, C. J. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00482 · Cited by 34
Stahl, S. M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008000 · Cited by 37
“…bupropion, a proven antidepressant with this same profile, appears to enhance these same neurotransmitters but through reuptake inhibition (norepinephrine and dopamine reuptake inhibition or NDRI) rather than through norepinephrine and dopamine disinhibition (NDDI actions) (Stahl et al., 2004).”
BackgroundSelf-citationCremer, J. N., Amunts, K., Schleicher, A., Palomero‐Gallagher, N., Piel, M., Rösch, F., & Zilles, K. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.054 · Cited by 30
Katz, A., Dusetzina, S., Farley, J., Ellis, A., Gaynes, B., Castillo, W. C., Stürmer, T., & Hansen, R. A. (2012) · Pharmacotherapy · doi:10.1002/j.1875-9114.2011.01020.x · Cited by 30
“For example, the serotonergic mechanism of SSRIs such as sertraline has been associated with a greater frequency of sexual dysfunction compared with the combined dopaminergic and noradrenergic mechanism of bupropion-SR.(36) However, three of our findings support the idea that the difference in the Figure 1.”
ResultBarrett, S. T., Geary, T. N., Steiner, A. N., & Bevins, R. A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4448-x · Cited by 30
Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
Lieslehto, J., Tiihonen, J., Lähteenvuo, M., Mittendorfer‐Rutz, E., Tanskanen, A., & Taipale, H. T. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13564 · Cited by 34
Prica, C., Hascoët, M., & Bourin, M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.028 · Cited by 31
Bupropion Induced Serotonin Syndrome: A Case Report
Thorpe, E. L., Pizon, A. F., Lynch, M. J., & Boyer, J. J. (2010) · Journal of Medical Toxicology · doi:10.1007/s13181-010-0021-x · Cited by 30
“In humans, some studies have concluded that bupropion has no serotonergic activity [15, 22].”
BackgroundBrody, A. L., London, E. D., Olmstead, R. E., Allen-Martinez, Z., Shulenberger, S., Costello, M. R., Abrams, A. L., Scheibal, D., Farahi, J. B., SHOPTAW, S. J., et al. (2010) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.06.004 · Cited by 30
Attention-Deficit/Hyperactivity Disorder
Bokor, G., & Anderson, P. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014543628 · Cited by 36
“Bupropion Bupropion (Wellbutrin(1)) is a dual action antidepressant that inhibits the reuptake of dopamine and norepinephrine.(143) A number of studies examined its effectiveness in ADHD.”
Backgroundpara-Trifluoromethyl-methcathinone is an allosteric modulator of the serotonin transporter
Niello, M., Cintulová, D., Hellsberg, E., Jäntsch, K., Holy, M., Ayatollahi, L. H., Cozzi, N. V., Freissmuth, M., Sandtner, W., Ecker, G. F., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.04.021 · Cited by 29
Pilot Evaluation of Bupropion for the Treatment of Hot Flashes
Perez, D. G., Loprinzi, C., Sloan, J., Novotny, P., Barton, D., Carpenter, L., Smith, D. R., Christensen, B., & Rummans, T. (2006) · Journal of Palliative Medicine · doi:10.1089/jpm.2006.9.631 · Cited by 29
Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Puga-Olguín, A., Flores-Soto, M. E., Nápoles-Medina, A. Y., Muñoz‐Carrillo, J. L., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2025) · Biomedicines · doi:10.3390/biomedicines13081831 · Cited by 33
“This mechanism avoids significant sedation, cognitive disturbances, and anticholinergic effects [120].”
Carbonyl reduction of bupropion in human liver
Molnari, J. C., & Myers, A. L. (2012) · Xenobiotica · doi:10.3109/00498254.2011.643416 · Cited by 28
“Bupropion is a norepinephrine/dopamine reuptake inhibitor (Stahl et al. 2004) and an antagonist at the nicotinic receptor (Slemmer et al.”
BackgroundKotagale, N. R., Tripathi, S. J., Aglawe, M. M., Chopde, C. T., Umekar, M. J., & Taksande, B. G. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.019 · Cited by 27
“Therefore bupropion is considered as an antidepressant with unique pharmacologic properties with distinct tolerability (Stahl et al., 2004).”
Masters, A. R., McCoy, M., Jones, D. R., & Desta, Z. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.02.018 · Cited by 27
Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse
Vento (2013) · PubMed · doi:10.4415/ann_13_04_14 · Cited by 26
Exposure to dilute concentrations of bupropion affects zebrafish early life stages
Franco, M. B., Andrade, T. S., Sousa-Moura, D., da Silva, M. L., Ferraz, I. B. M., Camargo, N. S., Domingues, I., Oliveira, R., & Grisólia, C. K. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.01.141 · Cited by 26
Biology of obesity and weight regain: Implications for clinical practice
Rogge, M. M., & Gautam, B. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12504 · Cited by 29
“, La Jolla, CA, USA) is a weak inhibitor of the neuronal reuptake of dopamine and norepinephrine (Stahl et al., 2004), its use in individuals with food-binging behavior may need to be considered carefully given the links between the hypodopamine and binge eating described by Blum et al.”
BackgroundTodor, I., Popa, A., Neag, M. A., Muntean, D. M., Bocșan, I. C., Buzoianu, A. D., Vlase, L., Gheldiu, A.-M., & Briciu, C. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3h03r · Cited by 30
Leone, F. T., & Evers‐Casey, S. (2012) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e318247cada · Cited by 26
“Bupropion SR is a nontricyclic antidepressant that acts in part by inhibiting uptake of dopamine from the accumbal synapse.(63) Bupropion SR is approximately equivalent in efficacy to NRT monotherapy, but most effectively promotes abstinence and controls withdrawal symptoms when combined with NRT and counseling.”
BackgroundCox, L. S., Faseru, B., Mayo, M. S., Krebill, R., Snow, T. M., Bronars, C. A., Nollen, N. L., Choi, W. S., Okuyemi, K. S., Salzman, G. A., et al. (2011) · Trials · doi:10.1186/1745-6215-12-22 · Cited by 29
“Bupropion acts, in part, by inhibiting norepinephrine and dopamine reuptake [61].”
BackgroundCavariani, M. M., Kiguti, L. R. D. A., Rosa, J. D. L., Leite, G. A. A., Silva, P. V. E., Pupo, A. S., & Kempinas, W. D. G. (2015) · Journal of Applied Toxicology · doi:10.1002/jat.3089 · Cited by 27
“Bupropion is an atypical antidepressant drug widely used in the treatment of major depressive disorder and smoke cessation (Stahl et al., 2004; Dwoskin et al., 2006).”
BackgroundCharacterization of the transporterB0AT3 (Slc6a17) in the rodent central nervous system
Hägglund, M. G., Hellsten, S. V., Bagchi, S., Ljungdahl, A., Nilsson, V. C., Winnergren, S., Stephansson, O., Rumaks, J., Svirskis, Š., Kluša, V., et al. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-54 · Cited by 24
Sidi, H., Razali, N. A., Choy, C. L., Roos, N. A. C., Baharudin, A., & Das, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220222145735 · Cited by 23
“As such, bupropion is linked to a unique clinical profile with an action on the firing of both dopaminergic and norepinephrine neural pathways [34, 12].”
InfluentialAoun, M. A., Meek, B. P., Clair, L., Wikstrom, S., Prasad, B., & Modirrousta, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13488 · Cited by 26
Raza, A., & Munir, M. (2024) · Frontiers in Physics · doi:10.3389/fphy.2024.1348407 · Cited by 23
Learned, S. M., Graff, O. X., Roychowdhury, S. M., Moate, R., Krishnan, K., Archer, G. E., Modell, J. G., Alexander, R., Zamuner, S., Lavergne, A., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111424931 · Cited by 33
“…serotonin (5-HT) and norepinephrine (NE) systems are most commonly used to treat MDD, there is also a rationale to suggest that dopaminergic (DA) mechanisms might be potentially relevant to antidepressant response (D’Aquila et al., 2000; Popick et al., 2006; Skolnick, 2005; Stahl et al., 2004).”
BackgroundSelf-citationAshrafi, F., Mousavi, S., & Karimi, M. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.6.1547 · Cited by 26
“Bupropion is the only antidepressant available with a dual effect on norepinephrine (NE) and dopamine (DA) neurotransmitter systems, therefore shares actions with psychostimulants (Stahl et al., 2004).”
BackgroundClopidogrel drug interactions: a review of the evidence and clinical implications
Lee, C. H., Franchi, F., & Angiolillo, D. J. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1814254 · Cited by 23
Seo, E. H., Yang, H.-J., Kim, S.-G., Park, S., Lee, S., & Yoon, H. (2021) · Psychiatry Investigation · doi:10.30773/pi.2021.0207 · Cited by 24
Maneeton, B., Maneeton, N., Eurviriyanukul, & Srisurapanont, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46849 · Cited by 27
“17 Possibly due to the lack of sero-tonergic activity, 18 it has less propensity to induce sexual dysfunction, weight gain, and a psychological side effect of apathy syndrome 19–22 than SSRIs.”
Martens, M. A., Seyfer, D. L., Andridge, R., Foster, J. E. A., Chowdhury, M., McClure, K. E., & Coury, D. L. (2012) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2012.06.006 · Cited by 24
Shahmohammadi, A., Ramezanpour, N., Siuki, M. M., Dizavandi, F., Ghazanfarpour, M., Rahmani, Y., Tahajjodi, R., & Babakhanian, M. (2019) · Post Reproductive Health · doi:10.1177/2053369119841166 · Cited by 22
“as weight gain and reports of sexual dysfunction with the antidepressants.(8) Accordingly, many researchers and consumers have focussed recently on the use of the phytoestrogens in healing the mood disorders.”
BackgroundSmeraldi, E., & Delmonte, D. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.828690 · Cited by 28
“Existing antidepressants [9,10] are still associated with a number of side effects: gastrointestinal (GI) disturbances, weight gain, sleep disturbances, sexual dysfunction and discontinuation effects [11-14].”
BackgroundLeon, M., & Woo, C. C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1013363 · Cited by 24
“Called Auvelity, it contains dextromethorphan, which is an anti-tussive that is a non-competitive antagonist for the NMDA receptor and to the sigma opioid receptor, and bupropion, an antidepressant on its own that increases synaptic norepinephrine and dopamine by decreasing their reuptake (Stahl et al., 2004; Iosifesc…”
BackgroundHerb‐drug interactions: A short review on central and peripheral nervous system drugs
Bernardo, J., & Valentão, P. (2024) · Phytotherapy Research · doi:10.1002/ptr.8120 · Cited by 25
“It enhances monoaminergic function by inhibiting norepinephrine and dopamine neuronal reuptake (Stahl et al., 2004).”
BackgroundEffects of Treatment for Tobacco Dependence on Resting Cerebral Glucose Metabolism
Costello, M. R., Mandelkern, M. A., SHOPTAW, S. J., Shulenberger, S., Baker, S. K., Abrams, A. L., Xia, C., London, E. D., & Brody, A. L. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.165 · Cited by 21
“The best-established mechanism of action of bupropion HCl is that it blocks the reuptake of dopamine (Balfour, 2001; Holm and Spencer, 2000; Horst and Preskorn, 1998; Stahl et al , 2004).”
Perkins, F. N., & Freeman, K. B. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.06.015 · Cited by 21
“Bupropion, which is clinically prescribed as Wellbutrin® or Zyban®, is a catecholamine reuptake inhibitor that is used clinically for depression, obesity, and smoking cessation (Patel et al., 2016; Stahl et al., 2004).”
BackgroundHamdy, M. M., Elbadr, M. M., & Barakat, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.04.003 · Cited by 21
A Greener Synthesis of the Antidepressant Bupropion Hydrochloride
Andrew, O. B., Sherwood, J. R., & Hurst, G. A. (2022) · Journal of Chemical Education · doi:10.1021/acs.jchemed.2c00581 · Cited by 20
Vázquez-Gómez, E., Arias, H. R., Feuerbach, D., Miranda‐Morales, M., Mihailescu, S., Targowska‐Duda, K. M., Jóźwiak, K., & García‐Colunga, J. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.06.059 · Cited by 24
Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex
Hudson, A. L., Lalies, M. D., & Silverstone, P. H. (2012) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y2012-045 · Cited by 20
Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans
Sager, J. E., Choiniere, J. R., Chang, J. S., Stephenson‐Famy, A., Nelson, W. L., & Isoherranen, N. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00189 · Cited by 20
Cheon, E., Lee, K., Park, Y., Lee, J.-H., Koo, B., Lee, S., & Sung, H.-M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000663 · Cited by 25
“On the other hand, bupropion is the only antidepressant known to have a dual effect on norepinephrine and dopamine neurotransmitter systems, but no known serotonergic activity.(39) Drugs with a diverse repertoire of mechanisms may be rationally combined to enhance sluggish serotonin neurotransmission, and enhancement…”
BackgroundLegakis, L. P., Karim-Nejad, L., & Negus, S. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05530-y · Cited by 20
Kennedy, G. J., & Marcus, P. (2005) · Drugs & Aging · doi:10.2165/00002512-200522040-00001 · Cited by 23
“[118] Sustained-release Combined therapy with two serotonergic anforms are available to obviate the need for divided tidepressants (e.”
BackgroundCarrasco, M. C., Vicens, P., Vidal, J., & Redolat, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.018 · Cited by 20
“The mechanism of action by which bupropion produces its therapeutic effects has not been fully understood (Stahl et al., 2004).”
BackgroundTafseer, S., Gupta, R., Ahmad, R. S., Jain, S., Bhatia, M. S., & Gupta, L. K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173073 · Cited by 20
Varshosaz, J., Zaki, M. R., Minaiyan, M., & Banoozadeh, J. (2015) · BioMed Research International · doi:10.1155/2015/571816 · Cited by 23
The Outcome of Unintentional Pediatric Bupropion Ingestions: A NPDS Database Review
Beuhler, M. C., Spiller, H. A., & Sasser, H. C. (2010) · Journal of Medical Toxicology · doi:10.1007/s13181-010-0027-4 · Cited by 19
Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200907141452 · Cited by 21
Marok, F. Z., Fuhr, L. M., Hanke, N., Selzer, D., & Lehr, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030331 · Cited by 20
Carratalá‐Ros, C., Olivares-García, R., Martínez-Verdú, A., Arias‐Sandoval, E., Salamone, J. D., & Correa, M. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05950-4 · Cited by 19
Poleszak, E., Szopa, A., Wyska, E., Wośko, S., Serefko, A., Właź, A., Pieróg, M., Wróbel, A., & Właź, P. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.06.008 · Cited by 19
Review: Pharmacotherapy for smoking cessation
Carrozzi, L., Pistelli, F., & Viegi, G. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808096136 · Cited by 23
“Sustained-release bupropion Bupropion is a non-tricyclic antidepressive drug, which inhibits neuronal reuptake of noradrenaline and dopamine, with minimal effect on the reuptake of serotonin and no inhibitory effect on monoamine oxidase [Stahl et al. 2004].”
Background
Metadata
- Authors
- Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S.
- Affiliations
- University of California San Diego (US)
- St. John Hospital & Medical Center (US)
- Corresponding author
- Modell, Jack G.
- ORCID
- Stahl, Stephen M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-13
- Volume
- 6
- Issue
- 4
- Pages
- 159-166
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC514842
- OpenAlex
- W2046809238
- Cited by
- 495
- References
- 92
- Citations by year
- 2026: 14 · 2025: 28 · 2024: 31 · 2023: 33 · 2022: 35 · 2021: 27 · 2020: 27 · 2019: 19 · 2018: 36 · 2017: 25 · 2016: 29 · 2015: 23 · 2014: 19 · 2013: 20 · 2012: 15
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- bupropion, norepinephrine reuptake inhibition, dopamine uptake inhibition, antidepressant mechanism, antidepressant efficacy, antidepressant tolerability, sexual dysfunction, weight gain, sedation, serotonergic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.